GlassScriptPhysician profile
Donald Frederick Bruner
NPI 1114641289
$2,572.63
in general payments reported to CMS, 2019-2025
8 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $185 · 2024: $728 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768 · Travel and Lodging: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.48 |
| Travel and Lodging | $804.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,566.51 | 2023-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $812.77 | 2023-2025 | Descovy, Yeztugo, Epclusa |
| Merck Sharp & Dohme LLC | $58.68 | 2023-2024 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $45.75 | 2024 | Egrifta Sv |
| Astrazeneca Pharmaceuticals LP | $31.83 | 2024 | Farxiga |
| Janssen Scientific Affairs, LLC | $23.29 | 2023 | Symtuza |
| Novo Nordisk INC | $19.86 | 2023 | Rybelsus, Ozempic |
| Janssen Biotech, INC. | $13.94 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Bruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.